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Figure 1 Inhaled hyperpolarised 3He MRI for a patient with severe asthma who had complete normalisation of 
MRI ventilation heterogeneity following dupilumab 300 mg administered subcutaneously every 2 weeks for 5 months. 
A representative coronal slice of the 3He MRI (in blue) co-registered to the 1H anatomical MRI of the thorax (in grey 
scale) acquired pre-salbutamol and post-salbutamol before and after treatment with dupilumab. White arrows spatially 
identify ventilation defects (regions of the lung that are not ventilated in a single breath-hold) pre-dupilumab that 
responded to dupilumab (but not salbutamol) such that those regions became ventilated following treatment. Note 
that only a representative two-dimensional coronal slice from the posterior lung has been shown for visualisation 
purposes (all anterior to posterior slices are presented in the online supplementary file 1).
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Ventilation heterogeneity in asthma could be due to 
many reasons. Luminal obstruction due to inflam-
matory cells or mucus, smooth muscle constriction 
and airway wall thickness could all contribute indi-
vidually or collectively to ventilation heterogeneity. 
Interleukin-4 and interleukin-13, acting through 
the common interleukin-4 receptor, have the poten-
tial to modulate all of these features of asthma.1 
Inhaled hyperpolarised gas MRI provides a way 
to regionally visualise and quantify the functional 
consequence of these features.2 Dupilumab is a 
fully human monoclonal antibody directed against 
the alpha-subunit of the interleukin-4 receptor.3 
Here, we report a severe asthmatic who showed 
significant improvement and normalisation of MRI 
ventilation heterogeneity and associated clinical 
and physiological variables with dupilumab treat-
ment, suggesting that dupilumab modulated various 
aspects of luminal airway obstruction.
A 39-year-old atopic woman (total serum immu-
noglobulin E 1009 kU/L and peripheral blood 
eosinophils 1200 cells/µL) was seen for asthma 
in January 2015. She had mixed obstructive and 
non-obstructive spirometry (forced expiratory 
volume in one second (FEV1) 1.42 L (44%pred), 
forced vital capacity (FVC) 1.72 L (44%pred) and total 
lung capacity (TLC) 3.78 L (71%pred)), with 13% 
reversibility to salbutamol. Her asthma severity and 
symptoms (asthma control questionnaire (ACQ) 
1.2) were driven by eosinophilic bronchitis (44% 
sputum eosinophils), airway hyperresponsiveness 
(42% decrease in FEV1 (1.42 to 0.82 L) with 0.9% 
saline inhalation during a methacholine challenge) 
and mucus plugging (CT mucus score4 8), despite 
being on budesonide 200 μg+formoterol 6 μg three 
puffs two times per day, beclomethasone hydroflu-
oroalkane metered-dose inhaler 100 μg four puffs 
two times per day and 2.5 mg prednisone. Exhaled 
nitric oxide (FeNO) was elevated at 47 ppb indi-
cating increased NO synthase activity, an indirect 
reflection of signal transducer and activator of tran-
scription 6 (STAT6) activation and interleukin-4 
receptor signalling. She also previously had inade-
quate asthma control (ACQ>1.5) with omalizumab 
375 mg administered subcutaneously every 4 weeks 
(for 6 months), mepolizumab 100 mg administered 
subcutaneously every 4 weeks (for 19 months) 
(both of which did not normalise her sputum eosin-
ophil per cent) and reslizumab 3 mg/kg adminis-
tered intravenously every 4 weeks (for 4 months) 
(normalised her sputum eosinophil per cent). She 
was then treated with dupilumab 300 mg adminis-
tered subcutaneously every 2 weeks for 5 months. 
Her ACQ improved to 0.6 (from 1.2) and was asso-
ciated with improvements in sputum eosinophilia 
(from 6.3% to 0% and no granules, but increased 
to 12.3% two weeks after last injection), airway 
mucus (CT mucus score4 1), hyperresponsiveness 
(7% decrease in FEV1 (1.90 to 1.76 L) with 5% 
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saline inhalation during a sputum induction) and FeNO (from 
27ppb to 11 ppb). These findings suggest multiple components 
of her airway disease were controlled by dupilumab, consistent 
with the drugs putative mechanism of action.
We measured the functional consequence of this response using 
3He MRI (figure 1). Pre-dupilumab MRI revealed focal ventilation 
defects bilaterally, that were largely non-responsive to salbutamol 
(ventilation defect per cent: pre-salbutamol=8% and post-salbu-
tamol=9%), a subset were spatially related to mucus plugging visu-
alised by CT. Following 5 months of dupilumab, MRI ventilation 
improved such that no residual ventilation defects were observed 
(ventilation defect per cent: pre-salbutamol=3% and post-salbu-
tamol=2%). Yet, spirometry continued to show severe airflow 
limitation with an FEV1 of 1.69 L (57%pred), which improved to 
1.93 L (65%pred) post-salbutamol.
This report suggests that MRI may be used to evaluate the 
functional consequence of normalising multiple contributors to 
airway obstruction and may contribute as an additional outcome 
measure to evaluate severe asthma therapeutics. By blocking both 
interleukin-4 and interleukin-13 signalling, dupilumab completely 
normalised ventilation defects and improved asthma control, 
suggesting that this may be a useful therapy when one compo-
nent (e.g. eosinophils) is not the dominant contributor to asthma 
severity.
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